Glenmark Pharmaceuticals Limited — PPTs, 23-05-2025: Investor Presentation

1. Financial Highlights:

Consolidated revenue for Q4 reached Rs 3,256.2 Cr, up 6.3% YoY, with strong growth in Europe (+19.9%) and Rest of World (+4.9%) offsetting a 5.4% decline in North America. FY25 revenue rose 12.8% to Rs 13,321.7 Cr, driven by India (+31.9%) and Europe (+17.6%). EBITDA margin held steady at 17.2%, with EBITDA of Rs 560.7 Cr. Adjusted PAT was Rs 346.6 Cr, a 10.6% margin. R&D investment totaled Rs 236.7 Cr (7.3% of revenue), reflecting commitment to innovation.

2. Strategic Initiatives & Growth Drivers:

New launches like Empagliflozin in India and RYALTRIS® in 45+ countries are fueling growth. UK approval of WINLEVI® sets up a FY26 launch. Focus on respiratory and injectable segments, plus advancement of innovative pipeline candidates—highlighted by IGI’s ISB 2001 receiving FDA Fast Track and moving to Phase 1 expansion—underpin future momentum.

3. Business Developments:

Litigation around generic Zetia® was settled. Glenmark expanded alliances with Menarini (EU), Yuhan (South Korea), and Grand Pharmaceutical (China), broadening its footprint. IGI showcased encouraging clinical data for ISB 2001 in oncology. Manufacturing is shifting from Swiss in-house to global CDMOs to improve efficiency.

4. Market Position & Competitive Advantage:

Glenmark is 2nd in Indian Dermatology and Respiratory markets, and 3rd in Cardiac. In Europe, its branded respiratory and dermatology products are gaining share. A strong innovation pipeline, strategic partnerships, and expanding global presence reinforce its specialty therapies and biologics differentiation.

5. Investor Implications:

Positive growth potential arises from branded momentum, market expansion, and innovation pipeline depth. Execution risks include North America market challenges and biologics integration. Continued R&D and global commercialization efforts position Glenmark well for sustainable advancement.